Preview

Cardiovascular Therapy and Prevention

Advanced search

THE EFFECTIVENESS OF CARVEDILOL AND EPROSARTAN IN PATIENTS WITH METABOLIC SYNDROME AND CHRONIC HEART FAILURE

https://doi.org/10.15829/1728-8800-2014-2-46-50

Abstract

Аim. of the study was to assess the effectiveness of carvedilol and eprosartan in addition to the traditional treatment (Nitrosorbid 30mg/day + Digoxin 0.25mg/day + TromboASS 100mg/day + Atorvastatin 20mg/day + Furosemid 40mg/day + Verospiron 50mg/day + Atenolol 12.5–25 mg/day) in patients with metabolic syndrome and chronic heart failure.

Materials and methods. 91 patients with MS and CHF included sharing mentioned criteria. Carvedilol in doses of 6,25 ÷ 25 mg/day and eprosartan in doses of 300 ÷ 600 mg/day were administered in addition to the traditional treatment.

Results. After 12 months of treatment systolic BP decreased by 23.6% and diastolic by 17.2%. Heart rate decreased by 23.1%, and exercise tolerance increased by 22.3%. Dynamics of the presented indicators are statistically significant.

Conclusion. Administration of an alpha-beta blocker carvedilol and angiotensin II receptor blocker eprosartan in the above dosages promote the longest remission of heart failure, improvement in functional class and regression of pathological remodeling.

About the Author

R. L. Dashnamirov
Научно-исследовательский институт кардиологии им. академика Дж. Абдуллаева Министерства здравоохранения Азербайджанской Республики, Баку
Azerbaijan


References

1. Butler J, Rodondi N, Figaro K. Metabolic Syndrome and the risk of cardiovascular disease in older adults. JACC 2006; 47 (8): 595–602.

2. Taylor HA Jr, Coady SA, Levy D, et al. Relationships of BMI to cardiovascular risk factors differ by ethnicity. Obesity (Silver Spring) 2010; 18 (8): 1638–45.

3. Almazov VA. Insulin resistance and arterial hypertension — the influence of moxonidine and metformine therapy. J Hypertens 2000; 18 (suppl. 2): S12.

4. Mamedov M, Suslonova N, Lisenkova I, et al. Metabolic syndrome prevalence in Russia: Preliminary results of a cross-sectional population study. Diabetic and Vascular Disease research 2007; 4 (1): 46–7.

5. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. JACC 2013; 62 (8): 697–703.

6. Ford ES, Giles WH, Dietz W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9.

7. Benetos A. Does Blood Pressure Control Contribute to a More Successful Aging? Hypertension 2005; Vol. 46 (2): 261–2.

8. Bittner V. Women and coronary heart disease risk factors. J Cardioyasc Risk 2002; 9 (6): 315–22.

9. Lakatta EG, Levy D. Arterial and Cardiac Aging: Major Shareholders in Cardiovascular Disease Enterprises: Part I: Aging Arteries: A “Set Up” for Vascular Disease. Circulation 2003; 107 (1): 139–46.

10. Mamedov MN, Perov NV, Kosmatova OV. Perspectives of correction of the metabolic syndrome: the impact of concomitant antihypertensive and lipid-lowering therapy on the level of total coronary risk and tissue insulin resistance. Cardiology 2003; 43 (3): 13–9. Russian (Мамедов М. Н., Перова Н. В., Косматова О. В. и др. Перспективы коррекций проявлений метаболического синдрома: влияние сочетанной гипотензивной и гиполипидемической терапии на уровень суммарного коронарного риска и тканевую инсулинорезистентность. Кардиология 2003; 43 (3): 13–9).

11. Chazova IE, Mychka VB. Metabolic syndrome. Moscow: Publishing House of Media Medica 2004; 47–9, 100–45. Russian (Чазова И. Е., Мычка В. Б. Метаболический синдром. М.: Изд-во Media Medica 2004; 47–9, 100–45).

12. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome — a new worldwide definition. A consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23 (5): 469–80.

13. Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring) 2013; 21 (1): 8–24.

14. Xun P, Wu Y, He Q, He K. Fasting insulin concentrations and incidence of hypertension, stroke, and coronary heart disease: a meta-analysis of prospective cohort studies. Am J Clin Nutr 2013; 98 (6): 1543–54.

15. Wang J, Sarnola K, Ruotsalainen S, et al. The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns. Atherosclerosis 2010; 210 (1): 237–42.

16. Li C, Ford ES, McGuire LC, Mokdad AH. Association of metabolic syndrome and insulin resistance with congestive heart failure: findings from the Third National Health and Nutrition Examination Survey. J Epidemiol Community Health 2007; 61 (1): 67–73.

17. Rizos EC, Spyrou A, Liberopoulos EN, et al. Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. The Open Cardiovascular Medicine J 2007; 1: 22–6.

18. Uzunlulu M, Oguz A, Yorulmaz E. The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. Int Heart J 2006; 47 (3): 421–30.

19. Packer M, MD, Bristow MR, MD, PhD, Cohn JN, MD, et al., for the U. S. Carvedilol Heart Failure Study Group. The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. N Engl J Med 2008; 334: 1349–55.


Review

For citations:


Dashnamirov R.L. THE EFFECTIVENESS OF CARVEDILOL AND EPROSARTAN IN PATIENTS WITH METABOLIC SYNDROME AND CHRONIC HEART FAILURE. Cardiovascular Therapy and Prevention. 2014;13(2):46-50. (In Russ.) https://doi.org/10.15829/1728-8800-2014-2-46-50

Views: 658


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)